Shanghai Cross-linked Pharmaceutical Research and Development

Shanghai Cross-linked Pharmaceutical Research and Development (now officially known as Shanghai Shangyao Cross Linked Pharmaceutical Technology) is a specialized biopharmaceutical R&D subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH). Established in 2012 and based in Shanghai, the company focuses on the discovery and development of next-generation biologics, particularly antibody-drug conjugates (ADCs) and therapeutic antibodies for oncology and autoimmune diseases. Its clinical pipeline features several advanced ADC candidates, including B003 (anti-HER2) and B-013 (anti-ROR1), as well as novel antibody combinations like B002. The company operates an integrated platform that covers antibody engineering, linker-payload synthesis, and pilot-scale manufacturing, serving as a core innovation hub for SPH's broader biopharmaceutical strategy.